Home Tags Topoisomerase I inhibitor

Tag: topoisomerase I inhibitor

Gilead Agrees to Collaborate on the Strata Precision Indications for Approved...

ADC Review | Editorial Team
Gilead Sciences and Strata Oncology have signed an agreement in which Gilead has agreed to collaborate on the Strata Precision Indications for Approved THerapies (Strata PATH™; NCT05097599) study by providing sacituzumab govitecan-hziy (Trodelvy®) for eligible patients with cancer.

Sacituzumab Govitecan Increases PFS for Patients With Most Common Type of...

Peter Hofland
Treatment with sacituzumab govitecan (Trodelvy®; Gilead Sciences), an antibody-drug conjugate (ADC), resulted in longer progression-free survival (PFS) compared to physician’s choice of chemotherapy in...

ESMO 2020: In Heavily-pretreated Metastatic Urothelial Cancer Sacituzumab Govitecan Shows 27%...

ADC Review | Editorial Team
Heavily-pretreated, cisplatin-eligible, patients benefit from treatment with sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy®; Immunomedics). This is the conclusion from an analysis of data from the pivotal...

First Patients Dosed in Phase II Study of Patritumab Deruxtecan in...

ADC Review | Editorial Team
A first patient was doses in a phase II clinical trial designed to evaluate patritumab deruxtecan (previously known as U3-1402), a HER3 directed DXd...
Speakers and attendees during the morning sessions on Wednesday December 11, 2019. during the San Antonio Breast Cancer Symposium being held at the Henry B. Gonzalez Convention Center in San Antonio, TX. This year is the 42nd Anniversary of the meeting where over 7,500 physicians, researchers, patient advocates and healthcare professionals from over 90 countries attended the meeting which features the latest research on breast cancer treatment and prevention. Photo Courtesy 2019 © MedMeetingImages/Todd Buchanan

SABCS 2019: DESTINY-Breast01 Trial of Trastuzumab Deruxtecan Shows Positive Results in...

ADC Review | Editorial Team
Detailed data from the global pivotal Phase II single-arm DESTINY-Breast01 trial (NCT03248492) of trastuzumab deruxtecan (DS-8201; fam-trastuzumab deruxtecan in the US only) were presented...

DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan’s Ministry of...

Peter Hofland
DS-8201, an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, has received SAKIGAKE Designation for the treatment of HER2-positive advanced gastric...

Breakthrough Therapy Designation for DS-8201 Confirms the Potential to Offer Substantial...

Peter Hofland
The U.S. Food and Drug Administration (FDA) earlier today confirmed that it has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody-drug conjugate...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X